Matrix metalloproteinase inhibitor CGS 27023A protects COMP and proteoglycan in the bovine articular cartilage but not the release of their fragments from cartilage after prolonged stimulation in vitro with IL-1 alpha.
Ganu
V
V
Novartis Institute for Biomedical Research, Summit, New Jersey 07901, USA. vishwas.ganu@pharma.novartis.com
Melton
R
R
Wang
W
W
Roberts
D
D
D000818:Animals; D064236:Cartilage Oligomeric Matrix Protein; D002358:Cartilage, Articular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D002417:Cattle; D016326:Extracellular Matrix Proteins / Q000378:metabolism*; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D006877:Hydroxamic Acids; D007375:Interleukin-1 / Q000494:pharmacology*; D007700:Kinetics; D064235:Matrilin Proteins; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D009924:Organ Culture Techniques; D011480:Protease Inhibitors / Q000494:pharmacology*; D011509:Proteoglycans / Q000378:metabolism*; D011719:Pyrazines; D011994:Recombinant Proteins / Q000494:pharmacology; D013449:Sulfonamides; D013997:Time Factors
C097658:CGS 27023A; D064236:Cartilage Oligomeric Matrix Protein; D016326:Extracellular Matrix Proteins; D006023:Glycoproteins; D006877:Hydroxamic Acids; D007375:Interleukin-1; D064235:Matrilin Proteins; D011480:Protease Inhibitors; D011509:Proteoglycans; D011719:Pyrazines; D011994:Recombinant Proteins; D013449:Sulfonamides; C577553:TSP5 protein, human; D008666:Metalloendopeptidases